Full-Time

Principal Scientist

Biocompatibility

Posted on 10/3/2025

Deadline 11/28/25
GE Healthcare

GE Healthcare

1-10 employees

Imaging, monitoring, and healthcare IT solutions

No salary listed

Remote in USA

Remote

Category
Biology & Biotech (7)
, , , , , ,
Requirements
  • Masters in physical/organic/biochemistry, toxicology, bioengineering, or and equivalent material science.
  • Expert in ISO 10993 (biological evaluation of medical devices) for surface contact materials and ISO 18562 (biocompatibility evaluation of breathing gas pathways)
  • Experience conducting material and chemical characterization of medical devices, physicochemical analyses of polymeric materials, metals, and ceramics.
  • Experience (10+ years) in design and development of medical devices that are categorized as FDA Class II and Class III.
  • Experience with residue analyses, biological evaluation, and toxicological risk assessment of medical devices with direct contact (physical contact with body tissue), indirect contact (fluid or gas pathways, prior to tissue contact), and transient contact (brief contact with body tissue); ability to design experiments for and derive thresholds of toxicological concern and tolerable exposure levels.
  • Excellent verbal and written communication and presentation skills with the ability to speak and write clearly and convincingly in English, tailoring communication methods to customer’s requirements.
  • Advanced experience and proficiency with MS Office word processing, spreadsheet, presentation, and collaboration applications.
Responsibilities
  • Serve as a lead scientist for biocompatibility related standards, design requirements, test methods, and interpret test results for the PCS business across its sub-segments, for products such as patient monitors, anesthesia systems, cardiology/ECG, home care, maternal/infant care, and clinical accessories
  • Interface with Patient Care Solutions leadership in advising, developing, and conducting biocompatibility risk assessments, as a key voice in developing product strategy.
  • Ensure standardized test methods across multiple material and device types, leveraging common data to derive meaningful conclusions on the potential for toxicological concern.
  • Oversee technical approaches (material selections, design, test methods, test execution) for products to ensure they designed according to biocompatibility science and standards, and lead efforts to ensure existing products remain state-of-the-art with such science and standards.
  • Evaluate materials for potential cytotoxicity, systemic toxicity, genotoxicity, carcinogenicity, degradation, leachables, or off-gassing; and incorporate adequate requirements to ensure low risk of potential toxicological risk in plastics design guidelines and technical design reviews.
Desired Qualifications
  • American Board of Toxicology Diplomate (DABT), or other national equivalent such as ERT.
  • Experience leading test lab operations that support medical device biocompatibility evaluations.
  • Experience in mechanical design (5+ years).
  • Experience as a lead convenor of a Technical Committee (TC) or Working Group (WG) of a Standards Development Organization (SDO) or National Standards Body (NSB) such as ISO, IEC, IEEE, ANSI, or AAMI.
  • Experience preparing communications for and interacting with multiple regulatory bodies world-wide such as FDA, NMPA, TGA, MHLW, PMDA, CDSCO, BfArM, ANSM, etc.
  • Experience with high risk, life supporting, and life-sustaining products.
  • Demonstrated life-long learner; eagerness to obtain new skills and knowledge.
  • Humility in understanding, but assertive when needed; willing to make decisions and assign clear priorities.
  • Strong oral and written communication skills. Strong interpersonal and leadership skills. Demonstrated ability to analyze and resolve problems.

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA-cleared MIM Contour ProtégéAI+ 2.0 accelerates radiation oncology planning.[1]
  • DeepHealth breast screening integration improved detection 21% in U.S. studies.
  • Intelerad strengthens cloud enterprise imaging and adjacent digital infrastructure.
  • Sonic DL and helium-free MRI can boost workflow speed and operating economics.
  • Record backlog and 2025 revenue of $20.6 billion support future software and services growth.

What critics are saying

  • Memory-chip, oil, and freight inflation already forced 2026 profit guidance lower.
  • Intelerad integration can delay cloud imaging revenue and distract sales execution.
  • FDA or clearance delays can slow AI product refreshes and MRI adoption.

What makes GE Healthcare unique

  • GE HealthCare spans imaging, ultrasound, patient care, and pharmaceutical diagnostics.[1]
  • Its 2023 spin-off created a focused, publicly traded healthcare technology company.[1]
  • The company combines hardware, software, and services across 100-plus countries.[1][3]

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at GE Healthcare who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Relocation Assistance

Company News

The Associated Press
Apr 9th, 2026
GE HealthCare integrates bkActiv ultrasound with Medtronic Stealth AXiS for real-time cranial surgery navigation

GE HealthCare has announced a digital integration between its bkActiv intraoperative ultrasound system and Medtronic's Stealth AXiS surgical navigation system, now commercially available for cranial procedures. The integration allows neurosurgeons to use bkActiv as a plug-and-play real-time visualisation solution during procedures. The system addresses "brain shift", a natural movement of the brain during surgery that reduces pre-surgical image accuracy. bkActiv provides live ultrasound images alongside pre-operative MRI or CT scans on the Stealth AXiS system, recently cleared by the FDA for cranial procedures in the United States. Features include sterilisable transducers, sensitive colour Doppler for blood flow visualisation, and remote control capability from the sterile field. The companies will showcase the integration at the American Association of Neurological Surgeons Annual Scientific Meeting in May 2026.

Business Wire
Mar 25th, 2026
GE HealthCare unveils photon-counting CT and ReadyFix fleet management at ACC.26

GE HealthCare is showcasing its cardiology portfolio at ACC.26, featuring AI-enabled imaging technologies and software solutions addressing cardiovascular disease, which kills over 900,000 Americans annually. The company received US FDA 510(k) clearance for Photonova Spectra, a photon-counting CT system with proprietary Deep Silicon detectors designed to provide ultra-high-definition cardiac imaging and improved plaque characterisation. GE HealthCare introduced ReadyFix fleet management solution for MAC VU360 ECG workstations, enabling remote diagnostics and software deployment to optimise device uptime. The company also announced a US collaboration with Gentuity, connecting customers with HF-OCT and Vis-Rx PRIME Micro-Imaging Catheter for enhanced coronary procedure visualisation. The $20.6 billion company serves patients globally with imaging, diagnostics and AI solutions across the cardiology care pathway.

Business Wire
Mar 23rd, 2026
GE HealthCare's photon-counting CT Photonova Spectra receives FDA clearance

GE HealthCare has received FDA 510(k) clearance for Photonova Spectra, a photon-counting computed tomography system powered by its Deep Silicon detector technology. The system directly counts individual photons and measures their energy, enabling higher spectral and spatial resolution compared to conventional CT systems that first convert X-rays into visible light. Photonova Spectra features 8-bin energy resolution, wide detector coverage and rapid 0.23-second rotation speed, supporting fast acquisition and detailed visualisation across multiple clinical specialties. The system automatically captures spectral and ultra-high definition spatial data simultaneously without requiring special protocols. The technology incorporates NVIDIA accelerated computing to process up to 50 times more data than conventional CT systems. GE HealthCare is collaborating with institutions including UW-Madison and Stanford Medicine to explore clinical applications and imaging protocols.

Yahoo Finance
Mar 17th, 2026
GE HealthCare appoints Stryker CEO Kevin Lobo to board of directors

GE HealthCare has appointed Kevin Lobo, chair and CEO of Stryker Corporation, to its board of directors effective 13 March. Lobo brings over 25 years of medical technology, operational and financial leadership experience to the role. Lobo has served as Stryker's CEO since October 2012 and board chair since July 2014. Previously, he held leadership positions at Johnson & Johnson, including president of Ethicon Endo Strategy, and at chemical and pharmaceutical company Rhône-Poulenc. His early career included finance roles at KPMG, Unilever and Kraft Canada. GE HealthCare chairman H. Lawrence Culp said Lobo's clinical expertise and track record of driving innovation would strengthen the board as the company pursues growth priorities in personalised, connected healthcare.

Yahoo Finance
Mar 16th, 2026
Arthur J. Gallagher leads with 17.9% revenue growth while Grand Canyon Education and GE HealthCare struggle

Arthur J. Gallagher, an insurance brokerage and consulting firm, stands out amongst cash-producing stocks with a 12.8% trailing 12-month free cash flow margin. The company has demonstrated strong revenue growth of 17.9% annually over the past two years and earnings per share growth of 17.7% annually over five years, outperforming peers. In contrast, Grand Canyon Education faces challenges with underwhelming student numbers and modest earnings growth of just 7.2% annually over five years, despite a 21.6% free cash flow margin. GE HealthCare also struggles with weak 2.7% annual revenue growth over two years and limited organic expansion. Arthur J. Gallagher, operating in approximately 130 countries, provides insurance brokerage, reinsurance and consulting services globally.

INACTIVE